This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
|Slideshows|April 13, 2018
Treating Adolescent Depression With Psychotherapy: A Quiz
Author(s)Sanno E. Zack, PhD
Empirically supported psychotherapeutic treatments have been shown to reduce symptoms of depression and build problem-solving skills in adolescents. Three of those treatments are discussed in this 10-question quiz.
Advertisement
Advertisement
Related to this article
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
4
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
5